Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05460611
Other study ID # 2022-14192
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 7, 2023
Est. completion date December 2025

Study information

Verified date May 2024
Source Montefiore Medical Center
Contact Janet Choi, BS
Phone (917)680-9907
Email janet.choi@einsteinmed.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Single-center, open-label, baseline-controlled, pilot study evaluating the use of a Nonablative 1470 nm laser for the treatment of androgenetic alopecia and scarring alopecia.


Description:

Single-center, open-label, baseline-controlled, pilot study evaluating the use of a Nonablative 1470 nm laser for the treatment of androgenetic alopecia and scarring alopecia. The study may enroll up to 10 participants looking for improvement in their hair loss. All participants will have biopsy-proven alopecia before enrollment. There will be two treatment arms with 5 participants in the androgenetic alopecia arm and 5 participants in the scarring alopecia arm. Multiple treatment areas of the scalp may be performed. Each subject will receive up to three treatments. Follow-up visits are planned for months 6, 9, 12, and 15. Standardized photography, hair density measurement of the treated scalp areas will be recorded Pre and Post Treatment at each visit. Measurement outcomes will be compared to baseline. During the initial visit, subjects who meet the study's eligibility criteria will receive the first treatment after signing informed consent form. For this study, the investigators will use non-ablative HALO laser (1470nm) (Sciton). The non-ablative fractionated treatments with minimal downtime provide synergistic benefit of minimizing tissue damage while improving treatment tolerance and efficiency. The laser works by creating micro-channels in the dermis of the pilosebaceous unit, while leaving bridges of untouched tissue for improved permeability, faster healing, and enhanced delivery of topical treatments. The laser creates controlled zones of coagulation within the dermis. The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by Sciton. Each laser treatment will take approximately 10 to 15 minutes per subject. Pretreatment procedure will consist of topical anesthetic then cleaning of the affected area of the scalp with antiseptic, either 70% ethanol or 3% hydrogen peroxide. The U.S. Food and Drug Administration (FDA) has approved the 1470 nm laser for dermatologic purposes. The follow up phase will consist of clinical assessments including before and after photographs graded by blinded observers and hair density evaluation using Canfield HairMetrix ® device. Subjects are instructed to inform clinical staff after the treatment if they experience any adverse events and will complete patient questionnaires, pain score, and self-assessment of hair growth.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Healthy males and females, = 18 years of age at time of informed consent, seeking treatment for hair loss. - Subject must voluntarily sign and date an IRB approved informed consent form - Subjects with diagnosis of biopsy proven androgenetic alopecia or scarring alopecia with hair loss recorded over the past 6 months - Able to read, understand and voluntarily provide written informed consent. - Subject is determined to be healthy, non-smoker who agrees not to make any changes to their daily hair treatment regime during the study. - Subjects able and willing to comply with the treatment protocol and follow-up schedule and requirements. - Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period. Exclusion Criteria: - Subject does not have the capacity to consent to the study - Subject has other types of alopecia of the scalp like alopecia areata - Use of minoxidil or 5-alpha reductase inhibitors (i.e., finasteride, dutasteride) 3 months prior to screening date. - History of intralesional steroid injections to the scalp in the last 12 months - Any medical condition that in the consideration of the investigator, would present an increased risk of a photosensitivity reaction to the subject. - Any previous surgical procedure in the treatment area in the past 12 months, or major surgery in the last 6 months. - Allergy or history of prior reaction to lidocaine - History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection), and/or any history of systemic chemotherapy for prior 12 months. - History or current use of the following prescription medications: i. Immunosuppressive medications/biologics, 6 months prior to and during the study ii. Accutane or other systemic retinoids within the past twelve months - Smoking or vaping in the past 12 months. - History of hyperlipidemia, diabetes mellitus, hepatitis, or bleeding disorders. - History of major depressive disorders or endocrine disorders including but not limited to; hypothyroidism, Hashimoto's thyroiditis, or hyperthyroidism.

Study Design


Intervention

Device:
Sciton HALO 1470nm Non-ablative laser
Patients will be treated with the 1470nm non-ablative laser.

Locations

Country Name City State
United States Montefiore Einstein Advanced Care Elmsford New York

Sponsors (2)

Lead Sponsor Collaborator
Montefiore Medical Center Sciton

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Live and Photographic assessment of hair loss GAIS (Global Aesthetic Improvement Scale)- Scored from -3 greatly decreased in hair growth and density to 3 greatly increased in hair growth and density. A score of zero represents no change. This is the baseline assessment. month 1
Primary Hair density using Canfield HairMetrix imaging device; average number of hairs per follicular unit as baseline assessment month 1
Primary Hair counts using Canfield HairMetrix imaging device; hair count per cm squared as baseline assessment month 1
Primary Live and Photographic assessment of hair loss GAIS (Global Aesthetic Improvement Scale)- Scored from -3 greatly decreased in hair growth and density to 3 greatly increased in hair growth and density. A score of zero represents no change. Month 2
Primary Live and Photographic assessment of hair loss GAIS (Global Aesthetic Improvement Scale)- Scored from -3 greatly decreased in hair growth and density to 3 greatly increased in hair growth and density. A score of zero represents no change. Month 3
Primary Live and Photographic assessment of hair loss GAIS (Global Aesthetic Improvement Scale)- Scored from -3 greatly decreased in hair growth and density to 3 greatly increased in hair growth and density. A score of zero represents no change. Month 6
Primary Live and Photographic assessment of hair loss GAIS (Global Aesthetic Improvement Scale)- Scored from -3 greatly decreased in hair growth and density to 3 greatly increased in hair growth and density. A score of zero represents no change. Month 9
Primary Live and Photographic assessment of hair loss GAIS (Global Aesthetic Improvement Scale)- Scored from -3 greatly decreased in hair growth and density to 3 greatly increased in hair growth and density. A score of zero represents no change. Month 12
Primary Live and Photographic assessment of hair loss GAIS (Global Aesthetic Improvement Scale)- Scored from -3 greatly decreased in hair growth and density to 3 greatly increased in hair growth and density. A score of zero represents no change. Month 15
Primary Hair density using Canfield HairMetrix imaging device; average number of hairs per follicular unit Month 6
Primary Hair density using Canfield HairMetrix imaging device; average number of hairs per follicular unit Month 9
Primary Hair density using Canfield HairMetrix imaging device; average number of hairs per follicular unit Month 12
Primary Hair density using Canfield HairMetrix imaging device; average number of hairs per follicular unit Month 15
Primary Hair counts using Canfield HairMetrix imaging device; hair count per cm squared month 6
Primary Hair counts using Canfield HairMetrix imaging device; hair count per cm squared month 9
Primary Hair counts using Canfield HairMetrix imaging device; hair count per cm squared month 12
Primary Hair counts using Canfield HairMetrix imaging device; hair count per cm squared month 15
Secondary Subject Satisfaction Please choose the option that better represents the change in how your hair looks OVERALL in the area treated?
Please choose the option that better represents the change in your hair THICKNESS in the area treated?
Please choose the option that better represents the change in your hair SHEDDING/LOSS in the area treated?
Please choose the option that better represents the change in your hair DARKNESS in the area treated.
Please choose the option that better represents the change in your hair DARKNESS in the area treated.
-3 = Greatly decreased
-2 = Moderately decreased
-1 = Slightly decreased
0 = No change
1 = Slightly increased
2 = Moderately increased
3 = Greatly increased
months 1
Secondary Subject Satisfaction Please choose the option that better represents the change in how your hair looks OVERALL in the area treated?
Please choose the option that better represents the change in your hair THICKNESS in the area treated?
Please choose the option that better represents the change in your hair SHEDDING/LOSS in the area treated?
Please choose the option that better represents the change in your hair DARKNESS in the area treated.
Please choose the option that better represents the change in your hair DARKNESS in the area treated.
-3 = Greatly decreased
-2 = Moderately decreased
-1 = Slightly decreased
0 = No change
1 = Slightly increased
2 = Moderately increased
3 = Greatly increased
month 2
Secondary Subject Satisfaction Please choose the option that better represents the change in how your hair looks OVERALL in the area treated?
Please choose the option that better represents the change in your hair THICKNESS in the area treated?
Please choose the option that better represents the change in your hair SHEDDING/LOSS in the area treated?
Please choose the option that better represents the change in your hair DARKNESS in the area treated.
Please choose the option that better represents the change in your hair DARKNESS in the area treated.
-3 = Greatly decreased
-2 = Moderately decreased
-1 = Slightly decreased
0 = No change
1 = Slightly increased
2 = Moderately increased
3 = Greatly increased
month 3
Secondary Subject Satisfaction Please choose the option that better represents the change in how your hair looks OVERALL in the area treated?
Please choose the option that better represents the change in your hair THICKNESS in the area treated?
Please choose the option that better represents the change in your hair SHEDDING/LOSS in the area treated?
Please choose the option that better represents the change in your hair DARKNESS in the area treated.
Please choose the option that better represents the change in your hair DARKNESS in the area treated.
-3 = Greatly decreased
-2 = Moderately decreased
-1 = Slightly decreased
0 = No change
1 = Slightly increased
2 = Moderately increased
3 = Greatly increased
month 6
Secondary Subject Satisfaction Please choose the option that better represents the change in how your hair looks OVERALL in the area treated?
Please choose the option that better represents the change in your hair THICKNESS in the area treated?
Please choose the option that better represents the change in your hair SHEDDING/LOSS in the area treated?
Please choose the option that better represents the change in your hair DARKNESS in the area treated.
Please choose the option that better represents the change in your hair DARKNESS in the area treated.
-3 = Greatly decreased
-2 = Moderately decreased
-1 = Slightly decreased
0 = No change
1 = Slightly increased
2 = Moderately increased
3 = Greatly increased
month 9
Secondary Subject Satisfation Please choose the option that better represents the change in how your hair looks OVERALL in the area treated?
Please choose the option that better represents the change in your hair THICKNESS in the area treated?
Please choose the option that better represents the change in your hair SHEDDING/LOSS in the area treated?
Please choose the option that better represents the change in your hair DARKNESS in the area treated.
Please choose the option that better represents the change in your hair DARKNESS in the area treated.
-3 = Greatly decreased
-2 = Moderately decreased
-1 = Slightly decreased
0 = No change
1 = Slightly increased
2 = Moderately increased
3 = Greatly increased
month 12
Secondary Subject Satisfaction Please choose the option that better represents the change in how your hair looks OVERALL in the area treated?
Please choose the option that better represents the change in your hair THICKNESS in the area treated?
Please choose the option that better represents the change in your hair SHEDDING/LOSS in the area treated?
Please choose the option that better represents the change in your hair DARKNESS in the area treated.
Please choose the option that better represents the change in your hair DARKNESS in the area treated.
-3 = Greatly decreased
-2 = Moderately decreased
-1 = Slightly decreased
0 = No change
1 = Slightly increased
2 = Moderately increased
3 = Greatly increased
month 15
See also
  Status Clinical Trial Phase
Completed NCT02591355 - Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment N/A
Withdrawn NCT03852992 - Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia Phase 2
Recruiting NCT06239207 - Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia Phase 2
Completed NCT04945226 - A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001 Phase 1/Phase 2
Completed NCT01548066 - The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss Phase 2
Completed NCT01437163 - Treatment of Androgenetic Alopecia in Males and Females N/A
Completed NCT01226459 - Clinical Trial in Females for Female Pattern Hair Loss Phase 3
Recruiting NCT06118866 - A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia Phase 2
Completed NCT06149221 - Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss N/A
Withdrawn NCT04882969 - Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia N/A
Completed NCT01231607 - Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Phase 3
Completed NCT04446429 - Anti-Androgen Treatment for COVID-19 N/A
Completed NCT02729415 - Point-of-Care Adipose-derived Cells for Hair Growth N/A
Completed NCT02279823 - A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia Phase 2
Not yet recruiting NCT01227031 - Pharmacogenomic Study of Androgenetic Alopecia N/A
Completed NCT00981461 - Treatment of Androgenetic Alopecia in Females, 9 Beam N/A
Completed NCT01451021 - A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss Phase 2
Completed NCT00151515 - A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Phase 3
Completed NCT03694067 - Androgenetic Alopecia and the JAK-STAT Pathway
Completed NCT03689452 - The Effect of Platelet Rich Plasma on Non-scarring Alopecia N/A